Low-concentration atropine sulfate nanomatrix eye drops with high permeability and preparation method thereof
Preparation of high permeability low-concentration atropine sulfate nanomatrix eye drops through nanotechnology, solving the problems of pharmacological instability and side effects of atropine sulfate eye drops at high concentrations, improving the control effect of adolescent myopia, and providing A stable and effective treatment regimen.
Patent Information
- Application Number
- CN202410280103.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-12
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-03-12
AI Technical Summary
The existing atropine sulfate eye drops have problems with pharmacological instability and major side effects at high concentrations, which are difficult to be widely used in commercialization. At the same time, the efficacy of low-concentration atropine is poor, making it difficult to effectively control the progress of myopia in adolescents.
Nanotechnology is used to form a nanomatrix with high permeability through high-pressure nanopreparation method. Combined with 0.01% atropine sulfate, a low-concentration atropine sulfate nanomatrix eye drops with high permeability were prepared, and the crosslinking reaction was carried out. and high-pressure homogenization method improve the drug loading capacity and permeability of the drug.
The high permeability and effective permeability of atropine sulfate are achieved, which reduces side effects and improves the control effect on myopia, providing a stable and effective treatment plan.
Smart Images

Figure CN118141759B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of modern chemical drugs, and particularly relates to a low-concentration atropine sulfate nano-matrix eye drop with high permeability and a preparation method thereof. Background Art
[0002] The overall myopia rate among children and adolescents is 52.7%, among which 14.3% are 6-year-olds, 35.6% are primary school students, 71.1% are junior high school students, and 80.5% are high school students. The myopia situation among adolescents in my country is very serious, and the occurrence of myopia among children and adolescents shows a trend of "low age and high incidence", which imposes a serious burden on society and families. In 2021, the Ophthalmology Branch of the Chinese Association of Traditional Chinese Medicine issued the "Guidelines for Appropriate Technologies for the Prevention and Control of Myopia in Children and Adolescents", pointing out that "the role of traditional Chinese medicine in the prevention and control of myopia in children and adolescents should be fully utilized"; in 2022, the General Office of the Ministry of Education of China issued the "National Key Work Plan for Comprehensive Prevention and Control of Myopia in Children and Adolescents", aiming to solidly promote the prevention and control of myopia among young people under the new situation on the basis of systematic planning.
[0003] How to adopt simple and effective control methods for myopia in children and adolescents is a top priority. Atropine sulfate is the only drug that has been proven by evidence-based medicine to effectively control the progression of myopia. Atropine sulfate can control the axial growth of myopia, thereby controlling the increase in myopia. Atropine sulfate has become a hot topic in the study of drug control of myopia in optometry.
[0004] Atropine sulfate is recognized worldwide as the first choice drug for effectively alleviating the progression of myopia and controlling axial growth. A five-year clinical study of atropine for the treatment of myopia (ATOM1) involving 400 Asian children aged 6 to 12 years found that the myopia progression and axial growth of 1% atropine eye drops within two years were (-0.28±0.92) d and (0.02±0.35) mm, respectively, while the placebo group was (-1.20±0.69) mm. Atropine treatment can reduce the average progression of myopia by about 77%. The results show that compared with placebo, the use of 1% atropine eye drops every night can reduce the progression of low and moderate myopia in children and adolescents. Gong, Qianwen, Liu, et al. published a paper titled "THERAPEUTIC EFFECT OF ATROPINE 1% IN CHILDREN WITH LOW MYOPIA" which showed that the same concentration of atropine was used to treat myopia. The results showed that 1% atropine was effective in preventing and treating myopia in children and adolescents. Subsequently, Audrey, Chia, Wei-Han, et al. conducted a prospective randomized double-blind clinical trial (ATOM2) in which 0.5%, 0.1%, and 0.01% atropine eye drops were applied to both eyes of myopic children once a night. The results showed that the average myopia progression in the 0.5%, 0.1% and 0.01% atropine groups was (-0.30±0.60), (-0.38±0.60), (-0.49±0.63)D in two years, and the average increase in axial length was (0.27±0.25), (0.28±0.28), (0.41±0.32)mm, respectively. Compared with the results of the ATOM1 placebo group, the three concentrations of atropine can effectively slow down the progression of myopia and axial growth. The research results were published in the paper "Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2)". Other clinical studies have also confirmed the above research results.
[0005] The above clinical trials have shown that high concentrations (1%, 0.5%, 0.1%) and low concentrations (0.05%, 0.02%, 0.01%) of atropine can effectively control myopic refraction and axial length growth. However, the effective concentration of atropine for controlling myopia remains unclear. Therefore, Yam et al. conducted a randomized controlled double-blind trial (LAMP1). After 1 year, the SE changes of 0.05%, 0.025%, 0.01% atropine group and placebo group were (-0.27±0.61), (-0.46±0.45), (-0.59±0.61), (-0.81±0.53)D, respectively (P<0.001), and the average growth of axial length was (0.20±0.25), (0.29±0.20), (0.36±0.29), and (0.41±0.22)mm, respectively (P<0.001). The results showed that low-concentration (0.05%, 0.02%, 0.01%) atropine eye drops can slow the progression of myopia, and among the three concentrations, 0.05% atropine has the most significant effect. The research results were published in the paper "Low-Concentration Atropine for Myopia". In the second phase of the LAMP2 study, Yam JC, Li FF, Zhang X and other researchers found that 0.05% atropine had the best effect among the three low concentrations, further proving that atropine has a dose-dependent effect in controlling myopia progression, that is, the higher the atropine concentration, the better the effect of slowing myopia progression. The research results were published in the paper "Two-Year Clinical Trial of the Low-Concentration Atropinefor Myopia Progression (LAMP) Study: Phase 2 Report".
[0006] In the ATOM2 and LAMP2 studies, all concentrations of atropine eye drops were well tolerated and had no significant adverse effects on quality of life. Fu Aicun et al. believed that atropine eye drops had no significant effect on intraocular pressure. Chia A, Li W, Tan D et al. found no evidence that daily use of atropine would cause retinal damage. From previous clinical trials, the main side effects of atropine eye drops are photophobia and blurred vision caused by pupil dilation after sphincter paralysis, especially when high concentrations of atropine eye drops are used. In addition, myopia regression occurs after discontinuation of atropine eye drops. Suffee Bibi Shaminah, Shipkolye Mohammad Ashiff, Lu Fan and other researchers found that myopia regression progressed slowly after atropine was discontinued, while low concentrations of atropine had the smallest regression and fewer adverse reactions. A large amount of data shows that atropine eye drops follow a dose-dependent effect in terms of effectiveness and side effects.
[0007] 0.01% atropine is increasingly used to treat juvenile myopia. In a 5-year clinical study of atropine for the treatment of myopia (ATOM), compared with the 0.50% concentration of atropine in the ATOM1 study, the 0.01% concentration of atropine slowed myopia progression by 59% in 2 years of treatment with minimal side effects. In the study of low-concentration atropine for the treatment of myopia progression, although 0.01% was less effective than 0.025% and 0.05% atropine, the difference was not significant, and 0.01% atropine was better at delaying myopia progression, reducing myopia progression by 27.0% and 27.7% 1 and 2 years after treatment, respectively. These studies have demonstrated the efficacy of 0.01% atropine in treating myopia in children.
[0008] Low-concentration atropine sulfate eye drops have obvious advantages in preventing myopia and have broad market prospects. Since the 1970s, the results of many clinical studies have shown that 1% atropine can effectively delay the development of myopia, but it may cause obvious adverse effects such as mydriasis, photophobia, blurred near vision, allergic conjunctivitis, and allergic blepharitis. With the advancement of scientific research, it has been clinically proven that low-concentration atropine of 0.01% can also effectively prevent and control myopia in adolescents, with fewer side effects, and is currently the best known means of preventing and controlling myopia in adolescents.
[0009] Atropine degrades by 5-7% every quarter in a neutral environment, and its degradation products are neurotoxic. This pharmacological instability makes it difficult to fully commercialize.
[0010] The nanomatrix is made of gelatin and hyaluronic acid through a high-pressure nano-preparation method, which opens up the original physical spatial structure of gelatin and hyaluronic acid, reduces the molecular weight, and rearranges the molecular spatial configuration to form new non-covalent bonds such as hydrogen bonds and hydrophobic bonds, thereby forming a new polymer material, thereby giving the nanomatrix drug-carrying capacity. Since the material has new physical and chemical properties through spatial reconstruction and can be similar to the polarity of the cell membrane, it can more easily penetrate the cell membrane and enter the cell, allowing the active compounds it carries to take effect in a timely manner.
[0011] Gelatin is formed by partial degradation of collagen in connective tissues such as animal skin, bone, fascia, and myometrium. It is composed of 18 amino acids, among which proline (Pro) and hydroxyproline (Hyp) are high in content. The molecular structure of gelatin is shown in the following formula (1):
[0012]
[0013] Gelatin solution can form a gel with a certain hardness and cannot flow. When the gelatin gel is stimulated by the environment, it will respond accordingly, that is, when the composition, pH value, ionic strength of the solution changes, and when the stimulation signals such as temperature, light intensity, electric field change, or when stimulated by specific chemical substances, the gel will mutate and show phase transition behavior.
[0014] Hyaluronic acid is a high-grade polysaccharide composed of D-glucuronic acid and N-acetylglucosamine. The molecular structure of hyaluronic acid is shown in the following formula (2):
[0015]
[0016] With its unique molecular structure and physical and chemical properties, hyaluronic acid displays many important physiological functions in the body, such as lubricating joints, regulating the permeability of blood vessel walls, regulating the diffusion and movement of proteins, water and electrolytes, and promoting wound healing.
[0017] Nanotechnology, also known as nanotechnology, is a technology that studies the properties and applications of materials with structural sizes ranging from 1 nanometer to 100 nanometers. The size of nanoparticles can affect the thermodynamic properties of entropy and enthalpy between cell receptors and drugs, and thus have a certain effect on the adhesion between them. Nanoparticles can also enter cells by passive penetration.
[0018] Nanomatrix utilizes the chemical structure characteristics of polysaccharides and proteins. It is easy for them to produce non-covalent bonds such as hydrogen bonds and hydrophobic bonds, so as to rearrange the spatial configuration of polysaccharides and proteins and form new high-molecular compounds.
[0019] Hyaluronic acid at 3400cm -1 The OH stretching vibration peak of gelatin is at 3432 cm -1The NH stretching vibration absorption peak at 2800 cm shifted to the low band, and the intensity increased significantly, indicating that the polysaccharide protein in the nanomatrix produced hydrogen bonds; -1 The characteristic peaks near the gelatin peak at 1673 cm -1 The absorption peak of amide I at 1665 cm -1 The carboxyl vibration absorption peak at 240 nm moves to the low-wave band and weakens, indicating that there is an obvious hydrogen bonding effect in the nanomatrix.
[0020] It is known that S=O at 1220cm -1 There is an obvious characteristic absorption peak at 1580cm -1 The nearby NH characteristic absorption peak weakens or disappears, representing the protonated NH3 in hyaluronic acid and gelatin. + With SO4 2- A strong electrostatic attraction occurs.
[0021] The formation of new hydrogen bonds and other non-covalent bonds between polysaccharides and polypeptides was identified by infrared spectrophotometry. Figure 1 , which leads to changes in its physical and chemical properties. Figure 2 This is the infrared electron microscopy spectrum of the nanomatrix. The microstructure is different from the infrared electron microscopy spectrum of gelatin (see Appendix Figure 3 ) and hyaluronic acid infrared electron microscopy spectra (attached Figure 4 ). Summary of the invention
[0022] The invention provides a low-concentration atropine sulfate nano-matrix eye drop with high permeability.
[0023] The invention also provides a method for preparing the low-concentration atropine sulfate nano-matrix eye drops with high permeability.
[0024] The technical solution of the present invention is achieved by the following methods:
[0025] The invention discloses a low-concentration atropine sulfate nano-matrix eye drop with high permeability, which is prepared from gelatin, hyaluronic acid, atropine sulfate and purified water.
[0026] The low-concentration atropine sulfate nanomatrix eye drops with high permeability are prepared from gelatin, hyaluronic acid, atropine sulfate and purified water to form an atropine sulfate nanomatrix eye drops with an atropine sulfate concentration of 0.01% and a nanomatrix concentration of 0.5%.
[0027] The low-concentration atropine sulfate nano-matrix eye drops with high permeability are prepared by the following method:
[0028] a. Preparation of 0.5% hyaluronic acid aqueous solution: Take hyaluronic acid, dissolve it in pure water, and after it is fully dissolved, prepare a 0.5% hyaluronic acid aqueous solution;
[0029] b. Preparation of proteoglycan solution: Weigh gelatin and add it to the 0.5% hyaluronic acid aqueous solution prepared in step a, fully dissolve it, and then irradiate it under ultraviolet light to perform a cross-linking reaction to obtain a proteoglycan solution;
[0030] c. Preparation of proteoglycan freeze-dried powder: The proteoglycan solution obtained in step b is placed in a cryopreservation tube, placed in a refrigerator, pre-frozen, and then placed in a freeze dryer for freeze drying to obtain proteoglycan freeze-dried powder;
[0031] d. Preparation of low-concentration atropine sulfate nanomatrix eye drops with high permeability: Take the proteoglycan freeze-dried powder obtained in step c and the atropine sulfate drug, mix them, add purified water, stir evenly to dissolve them, and form a mixed solution; use a high-pressure homogenizer to perform high-pressure homogenization nano-treatment on the mixed solution to obtain atropine sulfate nanomatrix eye drops with an atropine sulfate concentration of 0.01% and a nanomatrix concentration of 0.5%.
[0032] The high-osmotic-performance low-concentration atropine sulfate nanomatrix eye drops are preferably prepared by the following method:
[0033] a. Preparation of 0.5% hyaluronic acid aqueous solution: according to the mass ratio of hyaluronic acid to pure water of 0.5:100, weigh hyaluronic acid, dissolve it in pure water, and after it is fully dissolved, prepare a 0.5% hyaluronic acid aqueous solution;
[0034] b. Preparation of proteoglycan solution: According to the mass ratio of gelatin to hyaluronic acid of 12:1, gelatin is weighed and added to the 0.5% hyaluronic acid aqueous solution prepared in step a, and fully dissolved, and then irradiated under ultraviolet light to perform a cross-linking reaction to obtain a proteoglycan solution;
[0035] c. Preparation of proteoglycan freeze-dried powder: put the proteoglycan solution obtained in step b into a freezing tube, put it in a refrigerator, pre-freeze it at -20°C for 11 to 13 hours, and then put it into a freeze dryer, and start the machine according to the following program: keep it at 0°C for 3 to 5 hours, then keep it at -20°C for 3 to 5 hours, then keep it at -40°C for 7 to 9 hours, then keep it at -20°C for 2 to 4 hours, then keep it at -10°C for 2 to 4 hours, then keep it at 0°C for 2 to 4 hours, and finally keep it at 10°C for 2 to 4 hours to obtain proteoglycan freeze-dried powder;
[0036] d. Preparation of low-concentration atropine sulfate nanomatrix eye drops with high permeability: according to the mass ratio of proteoglycan lyophilized powder to atropine sulfate of 50:1, the proteoglycan lyophilized powder obtained in step c and the atropine sulfate drug are mixed, purified water is added, and stirred evenly to dissolve them to form a mixed solution; the mixed solution is subjected to high-pressure homogenization nano-treatment using a high-pressure homogenizer, and the pressure parameter is 700-900 Pa, and the treatment is circulated for 15-25 minutes each time to obtain atropine sulfate nanomatrix eye drops with a concentration of 0.01% atropine sulfate and a concentration of 0.5% nanomatrix.
[0037] The highly permeable low-concentration atropine sulfate nanomatrix eye drops are more preferably prepared by the following method:
[0038] a. Preparation of 0.5% hyaluronic acid aqueous solution: according to the mass ratio of hyaluronic acid to pure water of 0.5:100, weigh 0.5 parts by weight of hyaluronic acid, dissolve it in 100 parts by weight of pure water, and after it is fully dissolved, prepare a 0.5% hyaluronic acid aqueous solution for standby use;
[0039] b. Preparation of proteoglycan solution: According to the mass ratio of gelatin to hyaluronic acid of 12:1, 6 parts by weight of gelatin were added to 100 parts by weight of the 0.5% hyaluronic acid aqueous solution prepared in step a, and fully dissolved, and then heated at 5W / cm 2 Irradiate under ultraviolet light for 30 minutes to carry out cross-linking reaction to obtain a proteoglycan solution;
[0040] c. Preparation of proteoglycan freeze-dried powder: put the proteoglycan solution obtained in step b into a freezing tube, put it in a refrigerator, pre-freeze it at -20°C for 12 hours, and then put it into a freeze dryer, and start the machine according to the following program: keep it at 0°C for 4 hours, then keep it at -20°C for 4 hours, then keep it at -40°C for 8 hours, then keep it at -20°C for 3 hours, then keep it at -10°C for 3 hours, then keep it at 0°C for 3 hours, and finally keep it at 10°C for 3 hours to obtain proteoglycan freeze-dried powder;
[0041] d. Preparation of low-concentration atropine sulfate nanomatrix eye drops with high permeability: according to the mass ratio of proteoglycan freeze-dried powder: atropine sulfate of 50:1, take 50 parts by weight of the proteoglycan freeze-dried powder obtained in step c and 1 part by weight of atropine sulfate, mix them, add purified water to 10,000 parts by weight, stir evenly to dissolve them, and form a mixed solution; use a high-pressure homogenizer to perform high-pressure homogenization nano-treatment on the mixed solution, the pressure parameter is 800 Pa, and the treatment is repeated 3 times, each time for 20 minutes, to obtain atropine sulfate nanomatrix eye drops with a concentration of 0.01% atropine sulfate and a nanomatrix concentration of 0.5%.
[0042] The concentrations mentioned in this application document are all mass concentrations.
[0043] Nanomatrix concentration = mass of proteoglycan lyophilized powder / mass of solution.
[0044] The technical effect of the technical solution proposed in this application is demonstrated through the following Experiments 1 and 2.
[0045] Experiment 1: Applicability verification experiment of atropine sulfate detection method
[0046] Objective: To verify the applicability of the detection method for atropine sulfate, confirm that the detection method is suitable for the determination of the content of the product's characteristic ingredients, and use this method to determine the content of transdermal absorption and transmucosal absorption samples. The content of atropine sulfate was detected by referring to the content determination method under "Atropine Sulfate Eye Ointment" in Part II of the 2020 edition of the Chinese Pharmacopoeia.
[0047] 1.1 Methods
[0048] 1.1.1 Instruments
[0049] Shimadzu LC-20AT high performance liquid chromatograph, DAD detector, electronic balance AB135-S.
[0050] 1.1.2 Reagents
[0051] Acetonitrile (chromatographic grade, Dima Technology Co., Ltd.), water is Wahaha purified water (Hangzhou Wahaha Group Co., Ltd.), potassium dihydrogen phosphate (Tianjin Fengchuan Chemical Reagent Technology Co., Ltd.), sodium heptane sulfonate (Shanghai McLean Biochemical Technology Co., Ltd.), atropine sulfate reference substance (Beijing Zhongjian Beacon Metrology Technology Co., Ltd., batch number: drk-1966-980310, purity>98%).
[0052] 1.1.3 Chromatographic conditions
[0053] Column: Agilent Eclipse Plus C 18 (250 mm × 4.6 mm, 5 μm) chromatographic column;
[0054] Mobile phase: 0.05 mol / L potassium dihydrogen phosphate solution (containing 0.0025 mol / L sodium heptane sulfonate)-acetonitrile (84:16);
[0055] Detection wavelength: 225nm;
[0056] Column temperature: 30°C
[0057] The injection volume was 20 μl.
[0058] 1.1.4 Preparation of reference solution
[0059] Atropine sulfate stock solution (0.18 mg / mL): Take 9.3 mg of atropine sulfate reference substance, accurately weigh it, add water to dissolve it and quantify it into a 50 mL volumetric flask to make a solution containing 0.18 mg per 1 mL as the atropine sulfate stock solution.
[0060] Atropine sulfate working solution (9.11 μg / mL): Accurately measure 2.5 mL of atropine sulfate stock solution (0.18 mg / mL), dissolve it in water and quantify it into a 50 mL volumetric flask to make a solution containing 9.11 μg per 1 mL, which is used as the atropine sulfate working solution.
[0061] 1.1.5 Preparation of test solution
[0062] Take the sample solution, accurately measure 0.1mL and place it in a 2mL EP tube, add mobile phase to dilute to 1mL, and pass it through a 0.45μm microporous filter membrane to obtain.
[0063] 1.1.6 Determination
[0064] Accurately measure the test solution and reference solution, inject them into the liquid chromatograph respectively, measure and record the chromatogram according to the conditions described in "1.1.3" of this experiment. Calculate by peak area according to the external standard method.
[0065] 1.2 Validation of analytical methods
[0066] 1.2.1 Linearity and range
[0067] According to the method of "1.1", 5, 10, 15, 20, 40, 60, and 80 μL of atropine sulfate solution (9.11 μg / mL) were injected into the liquid chromatograph, and the peak area was determined. A standard curve was plotted with the content (X, μg) as the horizontal axis and the peak area (Y) as the vertical axis.
[0068] Atropine sulfate: y=311064.3228x-3031.9650r=0.9999.
[0069] The results showed that atropine sulfate had good linearity in the range of 0.05 μg to 0.73 μg. The results are shown in Table 1 and Appendix Figure 5 .
[0070] Table 1 Atropine sulfate standard curve data
[0071]
[0072] 1.2.2 Precision
[0073] 20 μL of atropine sulfate working solution (9.11 μg / mL) was accurately drawn, and the chromatogram was recorded according to the method in "1.1.6" of this experiment. The sample was injected 6 times continuously. The RSD of the peak area value of atropine sulfate in the working solution was 1.90%, indicating that the precision test met the requirements. The results are shown in Table 2.
[0074] Table 2 Atropine sulfate precision determination results
[0075]
[0076] 1.2.3 Stability
[0077] Accurately pipette 20 μL of the same test solution and inject it at 0, 2, 4, 6, 8, 10, 12, and 24 h, respectively. Determine according to the "1.1.6" method. The RSD of the atropine sulfate content within 24 h is 1.59%. The results show that the test solution is stable within 24 h. The results are shown in Table 3.
[0078] Table 3 Atropine sulfate stability test results
[0079]
[0080] 1.2.4 Repeatability
[0081] Prepare 6 test solutions according to "1.1.5", determine according to "1.1.6", and record the chromatogram. The average content of atropine sulfate is 95.16μg, and the RSD is 1.69%, which meets the requirements. The results are shown in Table 4.
[0082] Table 4 Atropine sulfate repeatability test results
[0083]
[0084] 1.2.5 Recovery rate
[0085] Determination of low concentration recovery rate (80%): Take the sample solution, accurately measure 0.05mL, place it in a 2mL EP tube, accurately add 0.4mL of "1.1.4" atropine sulfate working solution (9.11μg / mL), add mobile phase to dilute to 1mL, pass through a 0.45μm microporous filter membrane, determine according to the "1.1.6" method, record the chromatogram, calculate, and prepare (3 copies).
[0086] Determination of medium concentration recovery rate (100%): Take the sample solution, accurately measure 0.05mL, put it in a 2mL EP tube, accurately add 0.5mL of "1.1.4" atropine sulfate working solution (9.11μg / mL), add mobile phase to dilute to 1mL, pass through 0.45μm microporous filter membrane, determine according to "1.1.6" method, record the chromatogram, calculate, and obtain (3 copies).
[0087] High concentration recovery rate determination (120%): Take the sample solution, accurately measure 0.05mL, place it in a 2mL EP tube, accurately add 0.6mL of "1.1.4" atropine sulfate working solution (9.11μg / mL), add mobile phase to dilute to 1mL, pass through 0.45μm microporous filter membrane, determine according to "1.1.6" method, record the chromatogram, calculate, and obtain (3 copies).
[0088] The results are shown in Table 5. The average recovery rate was 101.64% and the RSD was 1.76%, which met the requirements.
[0089] Table 5 Atropine sulfate recovery determination results
[0090]
[0091] 1.3 Conclusion
[0092] In summary, this method is suitable for the determination of atropine sulfate content.
[0093] Experiment 2: Transdermal absorption effect of nano-atropine sulfate eye drops with different concentrations
[0094] Objective: To study the transdermal absorption effect of nano-atropine sulfate eye drops with different concentrations by in vitro transdermal and transmucosal administration experiments.
[0095] 1 Methods
[0096] 1.1 Instruments
[0097] Shimadzu LC-20AT high performance liquid chromatograph, DAD detector, electronic balance AB135-S, and improved Franz diffusion cell.
[0098] 1.2 Reagents
[0099] Acetonitrile (chromatographic grade, Dima Technology Co., Ltd.), water is Wahaha purified water (Hangzhou Wahaha Group Co., Ltd.), potassium dihydrogen phosphate (Tianjin Fengchuan Chemical Reagent Technology Co., Ltd.), sodium heptane sulfonate (Shanghai McLean Biochemical Technology Co., Ltd.), atropine sulfate reference substance (Beijing Zhongjian Beacon Metrology Technology Co., Ltd., batch number: drk-1966-980310, purity>98%).
[0100] Sample No. 1: blank group, normal saline.
[0101] Sample No. 2 (non-nano matrix): positive drug, 0.01% atropine sulfate eye drops, batch number: 20230511, Baotou Chaoju Eye Hospital.
[0102] Sample No. 3 (low-concentration nanomatrix): 0.01% atropine sulfate low-concentration nanomatrix eye drops.
[0103] The preparation method is as follows:
[0104] a. Preparation of 0.1% hyaluronic acid aqueous solution: according to the mass ratio of hyaluronic acid to pure water of 0.1:100, weigh 0.1g hyaluronic acid and dissolve it in 100g pure water. After it is fully dissolved, a 0.1% hyaluronic acid aqueous solution is prepared and set aside;
[0105] b. Preparation of proteoglycan solution: According to the mass ratio of gelatin to hyaluronic acid of 12:1, weigh 1.2g of gelatin and add it to 100g of 0.1% hyaluronic acid aqueous solution prepared in step a, fully dissolve it, and then 2 Irradiate under ultraviolet light for 30 minutes to carry out cross-linking reaction to obtain a proteoglycan solution;
[0106] c. Preparation of proteoglycan freeze-dried powder: put the proteoglycan solution obtained in step b into a freezing tube, put it in a refrigerator, pre-freeze it at -20°C for 12 hours, and then put it into a freeze dryer, and start the machine according to the following program: keep it at 0°C for 4 hours, then keep it at -20°C for 4 hours, then keep it at -40°C for 8 hours, then keep it at -20°C for 3 hours, then keep it at -10°C for 3 hours, then keep it at 0°C for 3 hours, and finally keep it at 10°C for 3 hours to obtain proteoglycan freeze-dried powder;
[0107] d. Preparation of 0.01% atropine sulfate low-concentration nanomatrix eye drops: according to the mass ratio of proteoglycan freeze-dried powder to atropine sulfate of 10:1, take 10g of the proteoglycan freeze-dried powder obtained in step c and 1g of atropine sulfate, mix them, add purified water to 10000g, stir evenly to dissolve them, and form a mixed solution; use a high-pressure homogenizer to perform high-pressure homogenization nano-treatment on the mixed solution, the pressure parameter is 800pa, and the treatment is repeated 3 times, each time for 20 minutes, to obtain atropine sulfate nanomatrix eye drops with an atropine sulfate concentration of 0.01% and a nanomatrix concentration of 0.1%.
[0108] Sample No. 4 (medium concentration nanomatrix): 0.01% atropine sulfate medium concentration nanomatrix eye drops.
[0109] The preparation method is as follows:
[0110] a. Preparation of 0.5% hyaluronic acid aqueous solution: according to the mass ratio of hyaluronic acid to pure water of 0.5:100, weigh 0.5g hyaluronic acid and dissolve it in 100g pure water. After it is fully dissolved, a 0.5% hyaluronic acid aqueous solution is prepared and set aside;
[0111] b. Preparation of proteoglycan solution: According to the mass ratio of gelatin to hyaluronic acid of 12:1, weigh 6g of gelatin and add it to 100g of 0.5% hyaluronic acid aqueous solution prepared in step a, fully dissolve it, and then 2 Irradiate under ultraviolet light for 30 minutes to carry out cross-linking reaction to obtain a proteoglycan solution;
[0112] c. Preparation of proteoglycan freeze-dried powder: put the proteoglycan solution obtained in step b into a freezing tube, put it in a refrigerator, pre-freeze it at -20°C for 12 hours, and then put it into a freeze dryer, and start the machine according to the following program: keep it at 0°C for 4 hours, then keep it at -20°C for 4 hours, then keep it at -40°C for 8 hours, then keep it at -20°C for 3 hours, then keep it at -10°C for 3 hours, then keep it at 0°C for 3 hours, and finally keep it at 10°C for 3 hours to obtain proteoglycan freeze-dried powder;
[0113] d. Preparation of 0.01% atropine sulfate medium concentration nanomatrix eye drops: according to the mass ratio of proteoglycan freeze-dried powder to atropine sulfate of 50:1, take 50g of the proteoglycan freeze-dried powder obtained in step c and 1g of atropine sulfate, mix them, add purified water to 10000g, stir evenly to dissolve them, and form a mixed solution; use a high-pressure homogenizer to perform high-pressure homogenization nano-treatment on the mixed solution, the pressure parameter is 800pa, and the treatment is repeated 3 times, each time for 20 minutes, to obtain atropine sulfate nanomatrix eye drops with an atropine sulfate concentration of 0.01% and a nanomatrix concentration of 0.5%.
[0114] Sample No. 5 (sub-high concentration nanomatrix): 0.01% atropine sulfate sub-high concentration nanomatrix eye drops. The preparation method is as follows:
[0115] a. Preparation of 1% hyaluronic acid aqueous solution: according to the mass ratio of hyaluronic acid to pure water of 1:100, weigh 1g hyaluronic acid and dissolve it in 100g pure water. After it is fully dissolved, a 1% hyaluronic acid aqueous solution is prepared and set aside;
[0116] b. Preparation of proteoglycan solution: According to the mass ratio of gelatin to hyaluronic acid of 12:1, weigh 12g of gelatin and add it to 100g of 1% hyaluronic acid aqueous solution prepared in step a, fully dissolve it, and then 2 Irradiate under ultraviolet light for 30 minutes to carry out cross-linking reaction to obtain a proteoglycan solution;
[0117] c. Preparation of proteoglycan freeze-dried powder: put the proteoglycan solution obtained in step b into a freezing tube, put it in a refrigerator, pre-freeze it at -20°C for 12 hours, and then put it into a freeze dryer, and start the machine according to the following program: keep it at 0°C for 4 hours, then keep it at -20°C for 4 hours, then keep it at -40°C for 8 hours, then keep it at -20°C for 3 hours, then keep it at -10°C for 3 hours, then keep it at 0°C for 3 hours, and finally keep it at 10°C for 3 hours to obtain proteoglycan freeze-dried powder;
[0118] d. Preparation of 0.01% atropine sulfate sub-high concentration nanomatrix eye drops: according to the mass ratio of proteoglycan freeze-dried powder to atropine sulfate of 100:1, take 100g of the proteoglycan freeze-dried powder obtained in step c and 1g of atropine sulfate, mix them, add purified water to 10,000g, stir evenly to dissolve them, and form a mixed solution; use a high-pressure homogenizer to perform high-pressure homogenization nano-treatment on the mixed solution, the pressure parameter is 800pa, and the treatment is repeated 3 times, each time for 20 minutes, to obtain atropine sulfate nanomatrix eye drops with an atropine sulfate concentration of 0.01% and a nanomatrix concentration of 1%.
[0119] Sample No. 6 (high concentration nanomatrix): 0.01% atropine sulfate high concentration nanomatrix eye drops.
[0120] The preparation method is as follows:
[0121] a. Preparation of 2% hyaluronic acid aqueous solution: according to the mass ratio of hyaluronic acid to pure water of 2:100, weigh 2g hyaluronic acid and dissolve it in 100g pure water. After it is fully dissolved, a 2% hyaluronic acid aqueous solution is prepared and set aside;
[0122] b. Preparation of proteoglycan solution: According to the mass ratio of gelatin to hyaluronic acid of 12:1, weigh 24g of gelatin and add it to 100g of 2% hyaluronic acid aqueous solution prepared in step a, fully dissolve it, and then 2 Irradiate under ultraviolet light for 30 minutes to carry out cross-linking reaction to obtain a proteoglycan solution;
[0123] c. Preparation of proteoglycan freeze-dried powder: put the proteoglycan solution obtained in step b into a freezing tube, put it in a refrigerator, pre-freeze it at -20°C for 12 hours, and then put it into a freeze dryer, and start the machine according to the following program: keep it at 0°C for 4 hours, then keep it at -20°C for 4 hours, then keep it at -40°C for 8 hours, then keep it at -20°C for 3 hours, then keep it at -10°C for 3 hours, then keep it at 0°C for 3 hours, and finally keep it at 10°C for 3 hours to obtain proteoglycan freeze-dried powder;
[0124] d. Preparation of 0.01% atropine sulfate sub-high concentration nanomatrix eye drops: according to the mass ratio of proteoglycan freeze-dried powder to atropine sulfate of 200:1, take 200g of the proteoglycan freeze-dried powder obtained in step c and 1g of atropine sulfate, mix them, add purified water to 10000g, stir evenly to dissolve them, and form a mixed solution; use a high-pressure homogenizer to perform high-pressure homogenization nano-treatment on the mixed solution, the pressure parameter is 800pa, and the treatment is repeated 3 times, each time for 20 minutes, to obtain atropine sulfate nanomatrix eye drops with an atropine sulfate concentration of 0.01% and a nanomatrix concentration of 2%.
[0125] 1.3 Chromatographic conditions
[0126] Column: Agilent Eclipse Plus C 18 (250 mm × 4.6 mm, 5 μm) chromatographic column;
[0127] Mobile phase: 0.05 mol / L potassium dihydrogen phosphate solution (containing 0.0025 mol / L sodium heptane sulfonate)-acetonitrile (84:16);
[0128] Detection wavelength: 225nm;
[0129] Column temperature: 30°C
[0130] The injection volume was 20 μl.
[0131] 1.4 Preparation of reference solution
[0132] Atropine sulfate stock solution (0.18 mg / mL): Take 9.3 mg of atropine sulfate reference substance, accurately weigh it, add water to dissolve it and quantify it into a 50 mL volumetric flask to make a solution containing 0.18 mg per 1 mL as the atropine sulfate stock solution.
[0133] Atropine sulfate working solution (9.11 μg / mL): Accurately measure 2.5 mL of atropine sulfate stock solution (0.18 mg / mL), dissolve it in water and quantify it into a 50 mL volumetric flask to make a solution containing 9.11 μg per 1 mL, which is used as the atropine sulfate working solution.
[0134] 1.5 Preparation of ex vivo mouse skin
[0135] Kunming mice were killed by cervical dislocation, and the abdominal skin was peeled off. The abdominal hair was trimmed, and the subcutaneous fat tissue was carefully removed. The mice were rinsed with saline; cut into small pieces (2.0 cm × 2.0 cm), immersed in saline, and stored in a refrigerator at 4°C for use within one week.
[0136] 1.6 Transdermal penetration test procedure
[0137] The experiment used a modified Franz diffusion cell. The prepared ex vivo skin was rinsed with physiological saline and placed between the sample chamber and the receiving chamber. The stratum corneum was facing upward and the dermis was in contact with the receiving solution. The bubbles were exhausted. The diameters of the sample chamber and the receiving chamber were both 2.2 cm. 2 , the transdermal area is 3.8cm 2 20 mL of saline was added to the receiving cell, 1 mL of sample was added to the donor cell, and the installed Franz diffusion cell was placed at (37 ± 0.5) °C for stirring, and a circulating water bath was used for heat preservation. The stirring speed of the magnetic stirrer was 350 r·min -1 At 0.5h, 1h, 2h, 4h, 8h, 16h, and 24h, take 1mL of the receiving solution and add an equal amount of fresh double distilled water. Take 7 samples in total. Blow dry the sample with an air pump, add 0.2mL of mobile phase, vortex and mix to fully dissolve it, filter it through a 0.45μm microporous filter membrane, take 20μL of the filtrate and inject it into HPLC to determine the content of atropine sulfate. Repeat twice.
[0138] Calculate the cumulative release percentage of atropine sulfate at different times according to the formula Q = P i / P0×100%, where P i is the cumulative release amount of atropine sulfate in the receiving solution measured at different times, P0 is the total amount of atropine sulfate added to the sample in the release cell, and Q is the cumulative release percentage at different times.
[0139] 1.7 Determination
[0140] Accurately measure the test solution and reference solution, inject them into the liquid chromatograph respectively, measure and record the chromatogram according to the conditions described in "1.3" of this experiment. Calculate by peak area according to the external standard method.
[0141] 2. Transdermal absorption sample test results
[0142] The results of the transdermal absorption samples are shown in Table 6 and Appendix Figure 6 , Attachment Figure 7 The results showed that no corresponding chromatographic peaks appeared at the atropine sulfate peak position in blank sample No. 1 and high-concentration sample No. 6, so no atropine sulfate component was detected; the atropine sulfate content of samples No. 2, No. 3, No. 4, and No. 5 gradually increased with the extension of time, and the atropine sulfate content reached the highest at 16 hours and then tended to stabilize. Among them, sample No. 4 had the best transdermal absorption effect. After 16 hours of transdermal absorption, the cumulative release percentages of atropine sulfate in samples No. 2, No. 3, No. 4, and No. 5 were 80.51%, 81.53%, 85.71%, and 80.82%, respectively.
[0143] Table 6 Cumulative release percentage of transdermal absorption samples (%)
[0144]
[0145] 3 Discussion and Conclusion
[0146] Nanomatrix, through nanotechnology, gelatin and hyaluronic acid are prepared into nanoscale, and then the amino group of the amino acid in the gelatin reacts with the carboxyl group of the hyaluronic acid to form an amide bond, so that the hydrogel has the characteristics of both gelatin and hyaluronic acid, and produces new physical and chemical properties.
[0147] The amino acids in gelatin contain amino (-NH2), imino (-NH), carboxyl (-COOH), and hydroxyl (-OH), while hyaluronic acid contains carboxyl (-COOH), hydroxyl (-OH), and amide (-CONH-). They can undergo a variety of reactions, such as acid-base, esterification, and Maillard reaction, to produce new functional groups, such as amide (-CON-) and ester (-COO-), which can organically combine gelatin and hyaluronic acid to form a new compound.
[0148] Nanomatrix is different from nano-scale gelatin and nano-scale hyaluronic acid. Their states in the solution should be different because the fluidity of the nanomatrix has changed greatly. Compared with gelatin and hyaluronic acid of the same concentration, its viscosity is much lower. Its microstructure has undergone fundamental changes. The average diameter detected by field emission transmission electron microscopy is 8-15nm. The larger its surface area, the more water molecules it contacts, and the weaker the interaction force between nanomatrix particles, resulting in a significant decrease in the viscosity coefficient of the liquid hydrogel. At the same time, it also makes the nanomatrix have very good permeability, which can infiltrate the skin stratum corneum faster, penetrate between cells, and even reach the level of crossing the cell membrane. Therefore, the liquid hydrogel has a stronger transdermal absorption effect.
[0149] The transdermal effect of the nanomatrix is not linearly related to its concentration. Its transdermal effect does not increase with increasing concentration. Through experimental structure, it was found that its transdermal effect is best when its concentration is 0.5%. This is mainly because there are still a large number of hydrogen bonds and ionic bonds inside the proteoglycan of the nanomatrix. When the concentration of the nanomatrix is greater than 0.5%, the chance of intermolecular collision increases, the intermolecular interaction force is enhanced, and its transdermal effect is weakened. BRIEF DESCRIPTION OF THE DRAWINGS
[0150] Figure 1 The formation of new hydrogen bonds and other non-covalent bonds between polysaccharides and polypeptides was compared by infrared spectrophotometry.
[0151] Figure 2 Infrared electron microscopy spectrum of nanomatrix (liquid hydrogel)
[0152] Figure 3 Infrared electron microscopy spectrum of gelatin matrix
[0153] Figure 4 Infrared electron microscopy spectrum of hyaluronic acid
[0154] Figure 5 Atropine sulfate standard curve
[0155] Figure 6 Transdermal absorption sample content determination chart
[0156] Figure 7 Chromatograms of transdermal absorption samples, where: Figure A is the chromatogram of the reference substance; Figure B is the chromatogram of sample No. 1; Figure C is the chromatogram of sample No. 2; Figure D is the chromatogram of sample No. 3; Figure E is the chromatogram of sample No. 4; Figure F is the chromatogram of sample No. 5; Figure G is the chromatogram of sample No. 6 DETAILED DESCRIPTION
[0157] Embodiment 1:
[0158] The low-concentration atropine sulfate nanomatrix eye drops with high permeability are prepared by the following method:
[0159] a. Preparation of 0.5% hyaluronic acid aqueous solution: according to the mass ratio of hyaluronic acid to pure water of 0.5:100, weigh 0.5g hyaluronic acid and dissolve it in 100ml pure water. After it is fully dissolved, a 0.5% hyaluronic acid aqueous solution is prepared and set aside;
[0160] b. Preparation of proteoglycan solution: According to the mass ratio of gelatin to hyaluronic acid of 12:1, weigh 6g of gelatin and add it to 100ml of 0.5% hyaluronic acid aqueous solution prepared in step a, fully dissolve it, and then 2 Irradiate under ultraviolet light for 30 minutes to carry out cross-linking reaction to obtain a proteoglycan solution;
[0161] c. Preparation of proteoglycan freeze-dried powder: put the proteoglycan solution obtained in step b into a freezing tube, put it in a refrigerator, pre-freeze it at -20°C for 11 hours, and then put it into a freeze dryer, and start the machine according to the following program: keep it at 0°C for 3 hours, then keep it at -20°C for 3 hours, then keep it at -40°C for 7 hours, then keep it at -20°C for 2 hours, then keep it at -10°C for 2 hours, then keep it at 0°C for 2 hours, and finally keep it at 10°C for 2 hours to obtain proteoglycan freeze-dried powder;
[0162] d. Preparation of low-concentration atropine sulfate nanomatrix eye drops with high permeability: according to the mass ratio of proteoglycan freeze-dried powder: atropine sulfate of 50:1, take 50g of the proteoglycan freeze-dried powder obtained in step c and 1g of atropine sulfate, mix them, add purified water to 10000ml, stir evenly to dissolve them, and form a mixed solution; use a high-pressure homogenizer (PandaPlus2000 of NiroSoavi, Italy) to perform high-pressure homogenization nano-treatment on the mixed solution, the pressure parameter is 700pa, and the treatment is repeated 3 times, each time for 15 minutes, and the high-pressure homogenizer obtains atropine sulfate nanomatrix eye drops with a concentration of 0.01% atropine sulfate and a nanomatrix concentration of 0.5%.
[0163] Embodiment 2:
[0164] The low-concentration atropine sulfate nanomatrix eye drops with high permeability are prepared by the following method:
[0165] a. Preparation of 0.5% hyaluronic acid aqueous solution: according to the mass ratio of hyaluronic acid to pure water of 0.5:100, weigh 0.5g hyaluronic acid and dissolve it in 100ml pure water. After it is fully dissolved, a 0.5% hyaluronic acid aqueous solution is prepared and set aside;
[0166] b. Preparation of proteoglycan solution: According to the mass ratio of gelatin to hyaluronic acid of 12:1, weigh 6g of gelatin and add it to 100ml of 0.5% hyaluronic acid aqueous solution prepared in step a, fully dissolve it, and then 2 Irradiate under ultraviolet light for 30 minutes to carry out cross-linking reaction to obtain a proteoglycan solution;
[0167] c. Preparation of proteoglycan freeze-dried powder: put the proteoglycan solution obtained in step b into a freezing tube, put it in a refrigerator, pre-freeze it at -20°C for 12 hours, and then put it into a freeze dryer, and start the machine according to the following program: keep it at 0°C for 5 hours, then keep it at -20°C for 5 hours, then keep it at -40°C for 9 hours, then keep it at -20°C for 4 hours, then keep it at -10°C for 4 hours, then keep it at 0°C for 4 hours, and finally keep it at 10°C for 4 hours to obtain proteoglycan freeze-dried powder;
[0168] d. Preparation of low-concentration atropine sulfate nanomatrix eye drops with high permeability: according to the mass ratio of proteoglycan freeze-dried powder: atropine sulfate of 50:1, take 50g of the proteoglycan freeze-dried powder obtained in step c and 1g of atropine sulfate, mix them, add purified water to 10000ml, stir evenly to dissolve them, and form a mixed solution; use a high-pressure homogenizer (PandaPlus2000 of NiroSoavi, Italy) to perform high-pressure homogenization nano-treatment on the mixed solution, the pressure parameter is 900pa, and the treatment is repeated 3 times, each time for 25 minutes, to obtain atropine sulfate concentration of 0.01%, nanomatrix concentration of 0.5% atropine sulfate nanomatrix eye drops.
[0169] Embodiment 3:
[0170] The low-concentration atropine sulfate nanomatrix eye drops with high permeability are prepared by the following method:
[0171] a. Preparation of 0.5% hyaluronic acid aqueous solution: according to the mass ratio of hyaluronic acid to pure water of 0.5:100, weigh 0.5g hyaluronic acid and dissolve it in 100ml pure water. After it is fully dissolved, a 0.5% hyaluronic acid aqueous solution is prepared and set aside;
[0172] b. Preparation of proteoglycan solution: According to the mass ratio of gelatin to hyaluronic acid of 12:1, weigh 6g of gelatin and add it to 100ml of 0.5% hyaluronic acid aqueous solution prepared in step a, fully dissolve it, and then 2 Irradiate under ultraviolet light for 30 minutes to carry out cross-linking reaction to obtain a proteoglycan solution;
[0173] c. Preparation of proteoglycan freeze-dried powder: put the proteoglycan solution obtained in step b into a freezing tube, put it in a refrigerator, pre-freeze it at -20°C for 12 hours, and then put it into a freeze dryer, and start the machine according to the following program: keep it at 0°C for 4 hours, then keep it at -20°C for 4 hours, then keep it at -40°C for 8 hours, then keep it at -20°C for 3 hours, then keep it at -10°C for 3 hours, then keep it at 0°C for 3 hours, and finally keep it at 10°C for 3 hours to obtain proteoglycan freeze-dried powder;
[0174] d. Preparation of low-concentration atropine sulfate nanomatrix eye drops with high permeability: according to the mass ratio of proteoglycan freeze-dried powder: atropine sulfate of 50:1, take 50g of the proteoglycan freeze-dried powder obtained in step c and 1g of atropine sulfate, mix them, add purified water to 10000ml, stir evenly to dissolve them, and form a mixed solution; use a high-pressure homogenizer (PandaPlus2000 of NiroSoavi, Italy) to perform high-pressure homogenization nano-treatment on the mixed solution, the pressure parameter is 800pa, and the treatment is repeated 3 times, each time for 20 minutes, to obtain atropine sulfate concentration of 0.01%, nanomatrix concentration of 0.5% atropine sulfate nanomatrix eye drops.
Claims
1. A low-concentration atropine sulfate nanomatrix eye drop with high permeability, characterized in that: The eye drops are prepared from gelatin, hyaluronic acid, atropine sulfate and purified water to form an atropine sulfate nanomatrix eye drop with an atropine sulfate concentration of 0.01% and a nanomatrix concentration of 0.5%. The eye drops are prepared by the following method: a. Preparation of 0.5% hyaluronic acid aqueous solution: according to the mass ratio of hyaluronic acid to pure water of 0.5:100, weigh hyaluronic acid, dissolve it in pure water, and after it is fully dissolved, prepare a 0.5% hyaluronic acid aqueous solution; b. Preparation of proteoglycan solution: According to the mass ratio of gelatin to hyaluronic acid of 12:1, gelatin is weighed and added to the 0.5% hyaluronic acid aqueous solution prepared in step a, and fully dissolved, and then irradiated under ultraviolet light to perform a cross-linking reaction to obtain a proteoglycan solution; c. Preparation of proteoglycan freeze-dried powder: put the proteoglycan solution obtained in step b into a freezing tube, put it into a refrigerator, pre-freeze it at -20°C for 11 to 13 hours, and then put it into a freeze dryer, and start the machine according to the following program: keep it at 0°C for 3 to 5 hours, then keep it at -20°C for 3 to 5 hours, then keep it at -40°C for 7 to 9 hours, then keep it at -20°C for 2 to 4 hours, then keep it at -10°C for 2 to 4 hours, then keep it at 0°C for 2 to 4 hours, and finally keep it at 10°C for 2 to 4 hours to obtain proteoglycan freeze-dried powder; d. Preparation of low-concentration atropine sulfate nanomatrix eye drops with high permeability: according to the mass ratio of proteoglycan lyophilized powder to atropine sulfate of 50:1, the proteoglycan lyophilized powder obtained in step c and the atropine sulfate drug are mixed, purified water is added, and stirred evenly to dissolve them to form a mixed solution; the mixed solution is subjected to high-pressure homogenization nano-treatment using a high-pressure homogenizer, and the pressure parameter is 700-900 Pa, and the treatment is circulated for 15-25 minutes each time to obtain atropine sulfate nanomatrix eye drops with an atropine sulfate concentration of 0.01% and a nanomatrix concentration of 0.5%, and the nanomatrix concentration is the mass of the proteoglycan lyophilized powder / the mass of the solution.
2. The low-concentration atropine sulfate nanomatrix eye drops with high permeability according to claim 1, characterized in that: The low-concentration atropine sulfate nano-matrix eye drops with high permeability are prepared by the following method: a. Preparation of 0.5% hyaluronic acid aqueous solution: according to the mass ratio of hyaluronic acid to pure water of 0.5:100, weigh 0.5 parts by weight of hyaluronic acid, dissolve it in 100 parts by weight of pure water, and after it is fully dissolved, prepare a 0.5% hyaluronic acid aqueous solution for standby use; b. Preparation of proteoglycan solution: According to the mass ratio of gelatin to hyaluronic acid of 12:1, 6 parts by weight of gelatin were added to 100 parts by weight of the 0.5% hyaluronic acid aqueous solution prepared in step a, fully dissolved, and then heated at 5W / cm 2 Irradiate under ultraviolet light for 30 minutes to carry out cross-linking reaction to obtain a proteoglycan solution; c. Preparation of proteoglycan freeze-dried powder: put the proteoglycan solution obtained in step b into a freezing tube, put it into a refrigerator, pre-freeze it at -20°C for 12 hours, and then put it into a freeze dryer, and start the machine according to the following program: keep it at 0°C for 4 hours, then keep it at -20°C for 4 hours, then keep it at -40°C for 8 hours, then keep it at -20°C for 3 hours, then keep it at -10°C for 3 hours, then keep it at 0°C for 3 hours, and finally keep it at 10°C for 3 hours to obtain proteoglycan freeze-dried powder; d. Preparation of low-concentration atropine sulfate nanomatrix eye drops with high permeability: according to the mass ratio of proteoglycan freeze-dried powder to atropine sulfate of 50:1, 50 parts by weight of the proteoglycan freeze-dried powder obtained in step c and 1 part by weight of atropine sulfate are mixed, purified water is added to 10,000 parts by weight, and stirred evenly to dissolve to form a mixed solution; the mixed solution is subjected to high-pressure homogenization nano-treatment using a high-pressure homogenizer, the pressure parameter is 800 Pa, and the treatment is repeated 3 times, each time for 20 minutes, to obtain atropine sulfate nanomatrix eye drops with an atropine sulfate concentration of 0.01% and a nanomatrix concentration of 0.5%, and the nanomatrix concentration is the mass of the proteoglycan freeze-dried powder / the mass of the solution.
